^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZG005

    i
    Other names: ZG005
    Associations

    News

    Trials
    Company:
    Suzhou Zelgen
    Drug class:
    PD1 inhibitor, TIGIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. (clinicaltrials.gov)
    P1/2, N=93, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial • Combination therapy • Metastases
    |
    cisplatin • etoposide IV • ZG005
    27d
    Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • ZG005
    3ms
    Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • ZG005
    3ms
    A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1/2, N=130, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    Zepsun (donafenib) • ZG005
    3ms
    A Study of ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=484, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    ZG005
    1year
    Preclinical pharmacology and safety studies of ZG005: an anti-PD-1/TIGIT bispecific mAb in a phase I clinical trial for advanced tumors (AACR 2023)
    The combination of ZG005 with chemotherapeutic-reagents, cisplatin and donafenib, enhanced their anti-tumor efficacies. PK/TK analyses indicate a prolonged ZG005 receptor occupancy over 80%, consistent with in vitro binding results that are attribute to the S228P mutation in the IgG4 hinge region to prevent Fab exchange and enhance stability. The IND application of ZG005 has been approved by both FDA and NMPA, and the molecule is currently in phase I clinical trials for advanced solid tumors at escalated dosing of 0.3~20 mg/kg, Q3W, via i.v. administration.
    P1 data • Preclinical • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    cisplatin • Zepsun (donafenib) • ZG005